Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Plus Therapeutics ( (PSTV) ) just unveiled an announcement.
On January 13, 2026, Plus Therapeutics entered into an underwriting agreement with Lake Street Capital Markets for an underwritten public offering of 39,473,684 shares of common stock and an equal number of warrants at $0.38 per unit, with a 30-day option for additional shares and warrants to cover over-allotments, which the underwriter exercised on January 14, 2026 for 5,921,052 additional warrants. The offering, which closed on January 15, 2026, generated approximately $13.3 million in net proceeds that the company plans to use for working capital and general corporate purposes, and it is subject to a series of post-offering restrictions, including 45-day lock-ups on new equity issuance and insider sales and a 120-day ban on variable rate financing transactions, measures that collectively stabilize the capital structure in the near term while modestly diluting existing shareholders as Plus Therapeutics continues funding its CNS cancer programs.
The most recent analyst rating on (PSTV) stock is a Hold with a $0.28 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.
The score is primarily held down by weak financial performance—large ongoing losses, significant cash burn, and volatile/declining revenue—suggesting elevated funding risk. Technical indicators reinforce the downside trend (price below key moving averages with negative MACD), while valuation is difficult to support due to negative earnings and no dividend yield.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Plus Therapeutics, Inc., headquartered in Houston, Texas, is a clinical-stage pharmaceutical and healthcare company focused on developing targeted radiotherapeutics and precision diagnostics for difficult-to-treat central nervous system (CNS) cancers, including leptomeningeal metastases and recurrent glioblastoma. Through its wholly owned subsidiary CNSide Diagnostics, LLC, the company also develops and commercializes proprietary laboratory-developed tests such as the CNSide CSF Assay Platform, which detects and quantifies tumor cells that have metastasized to the CNS to support patient management. Plus Therapeutics leverages image-guided local beta radiation, targeted drug delivery, and a supply chain built via strategic partnerships to advance and potentially commercialize its pipeline.
Average Trading Volume: 7,502,774
Technical Sentiment Signal: Sell
Current Market Cap: $40.34M
For an in-depth examination of PSTV stock, go to TipRanks’ Overview page.